Previous 10 |
Merrimack Pharmaceuticals (NASDAQ: MACK ): FY GAAP EPS of -$4.55. More news on: Merrimack Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018 . ...
On February 6, 2019, MacroGenics ( MGNX ) reported that the SOPHIA trial comparing margetuximab plus chemotherapy to Herceptin plus chemotherapy met the primary endpoint of progression free survival with a hazard ratio of 0.76 with an accompanying p-value of 0.033. This rather surprising res...
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ON Semiconductor Corporation (NASDAQ:ON), Entegris, Inc. (NASDAQ:ENTG), U...
News, Short Squeeze, Breakout and More Instantly...
Merrimack Pharmaceuticals Inc. Company Name:
MACK Stock Symbol:
NASDAQ Market:
Merrimack Pharmaceuticals Inc. Website:
2024-05-12 12:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidat...